ARCUTIS BIOTHERAPEUTICS INC (NASDAQ: ARQT)

ARCUTIS BIOTHERAPEUTICS INC

NASDAQ: ARQT (Arcutis Biotherapeutics, Inc.)

Kemas kini terakhir: 16 Jan, 9:01AM

26.22

-0.14 (-0.53%)

Tambah ke senarai pantauan

Penutupan Terdahulu	26.36
Buka	26.49
Jumlah Dagangan	114,798
Purata Dagangan (3B)	2,329,569
Modal Pasaran	3,211,745,280

Harga / Pendapatan (P/E Ke hadapan)	60.98
Harga / Jualan (P/S)	10.42
Harga / Buku (P/B)	20.30

Julat 52 Minggu	11.13 (-57%) — 31.77 (21%)
Tarikh Pendapatan	28 Oct 2025

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Biotechnology (US)	Menaik	Bercampur
	Biotechnology (Global)	Menaik	Bercampur
Stok	Arcutis Biotherapeutics, Inc.	Menaik	Menaik

AISkor Stockmoo

0.0

Konsensus Penganalisis	3.0
Aktiviti Orang Dalam	NA
Volatiliti Harga	-3.5
Purata Bergerak Teknikal	1.0
Osilator Teknikal	-0.5
Purata	0.00

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
ARQT	3 B	-	-	20.30
EXEL	12 B	-	18.38	5.49
MDGL	11 B	-	-	18.12
AXSM	9 B	-	-	127.15
PRAX	9 B	-	-	25.42
PTGX	5 B	-	123.88	8.04

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Sektor	Healthcare
Industri	Biotechnology
Gaya Pelaburan	Small Growth
% Dimiliki oleh Orang Dalam	1.95%
% Dimiliki oleh Institusi	108.79%

Julat 52 Minggu	11.13 (-57%) — 31.77 (21%)
Julat Harga Sasaran	29.00 (10%) — 37.00 (41%)
Tinggi	37.00 (Mizuho, 41.11%)	Beli
Median	31.00 (18.23%)
Rendah	29.00 (Goldman Sachs, 10.60%)	Pegang
Purata	32.33 (23.30%)
Jumlah	2 Beli, 1 Pegang
Harga Purata @ Panggilan	27.26

Syarikat	Tarikh	Harga Sasaran	Panggilan	Harga @ Panggilan
Needham	26 Jan 2026	31.00 (18.23%)	Beli	26.20
Mizuho	28 Nov 2025	37.00 (41.11%)	Beli	30.65
Goldman Sachs	30 Oct 2025	29.00 (10.60%)	Pegang	24.92

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
22 Jan 2026	Pengumuman	Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
21 Jan 2026	Pengumuman	Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
12 Jan 2026	Pengumuman	Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
08 Dec 2025	Pengumuman	Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
17 Nov 2025	Pengumuman	FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
13 Nov 2025	Pengumuman	Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
07 Nov 2025	Pengumuman	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Nov 2025	Pengumuman	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
30 Oct 2025	Pengumuman	Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
30 Oct 2025	Pengumuman	Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2026	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Keuntungan	-60.95%
Margin Operasi (TTM)	-37.25%
EPS Cair (TTM)	-1.04
Pertumbuhan Hasil Suku Tahunan (YOY)	32.80%

Jumlah Hutang/Ekuiti (D/E MRQ)	77.67%
Nisbah Semasa (MRQ)	3.55
Aliran Tunai Operasi (OCF TTM)	-110.94 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-66.54 M

Pulangan Atas Aset (ROA TTM)	-18.43%
Pulangan Atas Ekuiti (ROE TTM)	-70.57%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)